Burden and Regional Disparities of
MASH
‐Related Liver Cancer in the Asia‐Pacific Region From 1990 to 2023
Xiao‐Dong Zhou, Qin‐Fen Chen, Daniel Q. Huang, Hung N. Luu, Giovanni Targher, Christopher D. Byrne, Huai Zhang, Mazen Noureddin, Renyi Su, Jacob George, Zobair M. Younossi, Frank Tacke, Ming‐Hua Zheng ABSTRACT
Background & Aims
Metabolic dysfunction‐associated steatohepatitis (MASH) is an increasingly significant contributor to primary liver cancer in the Asia‐Pacific region, with substantial regional variation.
To quantify the burden and temporal trends of MASH‐related liver cancer across countries and subregions from 1990 to 2023.
Methods
Using the Global Burden of Disease (GBD) 2023 dataset, we analysed age‐standardized prevalence, deaths, and disability‐adjusted life years (DALYs) for MASH‐related liver cancer, assessing temporal trends, regional variation and associations with the Socio‐demographic Index (SDI). Decomposition analysis estimated the contributions of ageing, population growth and epidemiological changes.
Results
In 2023, the high‐income Asia‐Pacific region had the highest age‐standardized prevalence of MASH‐related liver cancer (1.19 per 100 000), followed by Oceania (0.98 per 100 000) and Australasia (0.88 per 100 000), with Central Asia the lowest (0.56 per 100 000). Across the Asia‐Pacific region, prevalence, mortality and DALYs generally increased with SDI, though patterns varied by subregion. The high‐income Asia‐Pacific region showed a distinct ‘increase–peak–decline’ pattern in both mortality and DALYs, whereas low‐ and middle‐income regions (i.e., South Asia, South‐east Asia and Central Asia) showed steady increases in prevalence. Pacific island nations experienced disproportionately higher DALYs despite their smaller populations. Decomposition analyses showed that ageing and population growth accounted for the largest proportions of the observed changes in East Asia (44.8% and 41.4%, respectively) and South Asia (41.1% and 30.1%, respectively), whereas epidemiological change was the largest contributor in Australasia (58.4%).
Conclusions
MASH‐related liver cancer is rising across the Asia‐Pacific region, with substantial regional variation, underscoring the need for region‐specific public health strategies.